|1.||Albert, Daniel H: 9 articles (07/2011 - 04/2006)|
|2.||Davidsen, Steven K: 7 articles (07/2011 - 04/2006)|
|3.||Glaser, Keith B: 5 articles (03/2010 - 04/2006)|
|4.||Tapang, Paul: 4 articles (07/2011 - 04/2006)|
|5.||Zhou, Jianbiao: 3 articles (01/2009 - 07/2008)|
|6.||Chen, Chien-Shing: 3 articles (01/2009 - 07/2008)|
|7.||Luo, Yanping: 2 articles (07/2011 - 04/2006)|
|8.||Sakamoto, Kathleen M: 2 articles (03/2010 - 04/2007)|
|9.||Segreti, Jason A: 2 articles (06/2009 - 02/2009)|
|10.||Fryer, Ryan M: 2 articles (06/2009 - 02/2009)|
|1.||Hepatocellular Carcinoma (Hepatoma)
01/01/2009 - "The phase I trial for ABT-869 was recently completed and it demonstrated respectable efficacy in solid tumors including lung and hepatocellular carcinoma with manageable side effects. "
12/01/2008 - "ABT-869, a multi-targeted tyrosine kinase inhibitor, in combination with rapamycin is effective for subcutaneous hepatocellular carcinoma xenograft."
|2.||Hypertension (High Blood Pressure)
06/01/2009 - "In SCID mice, the ACE inhibitor, enalapril (C(20)H(28)N(2)O(5) x C(4)H(4)O(4)) at 30 mg/kg, prevented hypertension, with no attenuation of the antitumor efficacy of ABT-869. "
02/01/2009 - "To assess the utility of ETA receptor blockade in controlling hypertension with RTK inhibition, we evaluated the ability of atrasentan to block hypertension with ABT-869 in conscious, telemetry-instrumented rats. "
02/01/2009 - "ETA receptor blockade with atrasentan prevents hypertension with the multitargeted tyrosine kinase inhibitor ABT-869 in telemetry-instrumented rats."
06/01/2009 - "To evaluate optimal therapeutic approaches to prevent hypertension with VEGF receptor inhibition, we characterized the dose-dependent effects of seven antihypertensive agents from three mechanistic classes [angiotensin-converting enzyme inhibitors (ACEis), angiotensin receptor blockers (ARBs), calcium channel blockers (CCBs)] on hypertension induced by ABT-869 in conscious telemetry rats. "
06/01/2009 - "ABT-869 demonstrates tumor growth inhibition in multiple preclinical animal models and in early clinical trials. "
01/01/2009 - "Tumor cavitation and reduction of contrast enhancement after ABT-869 treatment supported the antiangiogenic activity. "
07/01/2008 - "ABT-869 showed a five-fold inhibition of tumor growth in comparison with vehicle control. "
08/01/2006 - "Surprisingly, inhibiting HIF-1 in tumors treated with the angiogenesis inhibitor ABT-869 did not produce much added benefit compared with ABT-869 treatment alone, suggesting that the combination of an angiogenesis inhibitor with a HIF-1 inhibitor may not be a robust therapeutic regimen. "
04/01/2006 - "These results support clinical assessment of ABT-869 as a therapeutic agent for cancer."
07/01/2011 - "We characterized the mechanism of action of ABT-869 by examining vascular changes after treatment (25 mg/kg per day) in HT1080 fibrosarcoma and SW620 colon carcinoma cells, using immunohistochemistry, dynamic contrast enhanced-magnetic resonance imaging (DCE-MRI), and hypoxic protein detection. "
04/01/2006 - "In tumor growth studies, ABT-869 exhibits efficacy in human fibrosarcoma and breast, colon, and small cell lung carcinoma xenograft models (ED50 = 1.5-5 mg/kg, twice daily) and is also effective (>50% inhibition) in orthotopic breast and glioma models. "
|5.||Small Cell Lung Carcinoma (Small Cell Lung Cancer)
|1.||Protein-Tyrosine Kinases (Tyrosine Kinase)
|4.||Biological Markers (Surrogate Marker)
|6.||tyrosine receptor (receptor, tyrosine)
|7.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|8.||Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)
|9.||N- (4- (3- amino- 1H- indazol- 4- yl)phenyl)- N1- (2- fluoro- 5- methylphenyl)urea
|10.||Angiotensin Receptor Antagonists
|1.||Heterologous Transplantation (Xenotransplantation)